LLL

Braving New Frontiers in Cancer Monitoring - Learn Look Locate (LLL) Hosts Educational Natera™ Site for Personalized Signatera™ Tests

Retrieved on: 
Monday, December 11, 2023
Empowerment, Woman, DNA, LLL, Medical director, Neoplasm, Breast cancer, Patient, Natera, MRD, Genetic testing, Cancer, Diagnosis, Breast reconstruction, Aftercare, Recurrence, Knowledge, Education, Vaccine, Medical imaging, Mammography

TUCSON, Ariz., Dec. 11, 2023 /PRNewswire/ -- Following a previous collaboration with Natera, a global cell-free DNA testing leader, LLL announced that it would host a dedicated webpage,  for Natera's revolutionary molecular residual disease assay (MRD) test: Signatera. MRD is used to describe the small amount of residual cancer cells that patients retain after cancer treatment and is used as a major predictor of relapse. The new LLL page will highlight the benefits of Signatera, while also giving patients and readers access to LLL's vast archive of breast cancer resources.

Key Points: 
  • The Signatera MRD assay can detect cancer recurrence far earlier than conventional methods by monitoring circulating tumor DNA (ctDNA).
  • "Signatera takes cancer management to a whole new level," said Dr. Barry Rosen, Senior Medical Advisor for LLL.
  • Dedicated to fostering inclusive education on breast health and cancer, Learn Look Locate passionately delivers the latest advancements, ensuring every individual is empowered with knowledge.
  • Cynthia's journey fuels our mission, ensuring no one feels as scared and uneducated as she did during her breast cancer diagnosis.

NCSOFT at G-STAR 2023: Unleashing New Global Line-ups Across Various Genres

Retrieved on: 
Thursday, November 16, 2023
Speech, Weapon, LLL, GMT, IP, BSS, Nintendo Switch, NCSOFT, Blade & Soul, Element, MMO, RPG, MMORTS, Atmosphere, Communication, Project M, Telescopic sight, Video game

PANGYO, South Korea, Nov. 16, 2023 /PRNewswire/ -- NCSOFT, a global premier game developer and publisher, today revealed its new global line-ups during the on-site event, 'Opening Speech,' at G-STAR 2023 in Busan, Korea, taking place from November 16 to 19.

Key Points: 
  • Moonyoung Choi, Principal Development Management Officer at NCSOFT, said, "Our entire development teams, and NCSOFT as a whole, have dedicated ourselves to showcase a diverse array of enjoyable experiences across various genres here at G-STAR."
  • He further emphasized, "Moving forward, we will remain committed to delivering great games by maintaining close communication and sharing our development progress with our fans."
  • At this year's G-STAR, NCSOFT brings hands-on experience for three projects: the shooter 'LLL,' the action battel brawler 'BATTLE CRUSH,' and the collectible role-playing game 'Project BSS.'
  • BATTLE CRUSH, NCSOFT's first-ever Nintendo Switch title, is an action-packed battle brawler capturing the interest of gamers around the globe.

Learn-Look-Locate Strengthens Growing Panel of Advisors With Influential Trailblazers in Cancer Research, Genetic Testing, Artificial Intelligence, and Restorative Tattooing: Dr. Maryam Lustberg, Lauren Giannetti Sferrazza, Stacey Stevens, and Marnie Rust

Retrieved on: 
Thursday, May 18, 2023
Survivor, Partnership, Education, Friends, Myriad Genetics, Genetic counseling, Heredity, Breast, AAM, Cancer, Yale Cancer Center, Risk assessment, Woman, Wall Street, Associate, LLL, Yale School of Medicine, Genetics, Estate (law), Patient, Breast cancer, Breast disease, Chief Medical Advisor to the President, Internal medicine, Yale University, Diagnosis, CPCP, MPH, Mammography, News, Thyroid cancer, Disease, Medical imaging, MD

Founded by breast cancer survivor, Cynthia Jordan, LLL represents a modern kind of global education hub for breast cancer support.

Key Points: 
  • Founded by breast cancer survivor, Cynthia Jordan, LLL represents a modern kind of global education hub for breast cancer support.
  • Dr. Lustberg is an acclaimed physician and researcher with an extensive background in all-phase clinical trials and breast cancer translational research.
  • Lauren Giannetti Sferrazza, MS CGC, is a certified genetic counselor who currently practices as a National Medical Science Liaison in Oncology at Myriad Genetics.
  • And in addition, LLL and Dr. Charles Weaver already release a monthly Breast Cancer Newsletter that offers support from diagnosis through treatment, and into survivorship.

Learn Look Locate and Sirius Medical Partner to Educate About Tumor Localization for Breast Cancer

Retrieved on: 
Thursday, April 27, 2023
Partnership, GPS, Surgeon, Neoplasm, Breast, Cancer, Woman, LLL, Patient, Social media, Caregiver, Breast cancer, Medical imaging

TUCSON, Ariz., April 27, 2023 /PRNewswire/ -- Learn Look Locate (LLL) partners with Sirius Medical, a leader in surgical marker navigation, to help educate patients and caregivers about tumor localization, a common procedure used to mark the location of the tumor or abnormal breast tissue prior to surgery for early-stage breast cancer.

Key Points: 
  • TUCSON, Ariz., April 27, 2023 /PRNewswire/ -- Learn Look Locate (LLL) partners with Sirius Medical, a leader in surgical marker navigation, to help educate patients and caregivers about tumor localization, a common procedure used to mark the location of the tumor or abnormal breast tissue prior to surgery for early-stage breast cancer.
  • There will be a dedicated page on the website that will include information:
    "At Sirius Medical, it is our mission to improve care for cancer patients," said Dana Troup, US Chief Commercialization Officer.
  • "We are proud to collaborate with Learn Look Locate to further the mission of educating and empowering women about their options during their breast cancer journey."
  • Traditional tumor localization involves placing a wire into the breast on the day of surgery, which is very uncomfortable and imprecise.

QinetiQ US Awarded $92.6M Digital Night Vision Technology (DNVT) IDIQ Contract

Retrieved on: 
Thursday, March 30, 2023
Army, IDIQ, United States Department of Defense, Research, Science, LLL, S&T, Algorithm, United States Department of the Army, Qinetiq, SA, Department of Defence, Television, United States Army

Lorton, VA, March 30, 2023 (GLOBE NEWSWIRE) -- QinetiQ US, a leading defense company providing mission-critical solutions to create, test, and use the latest technologies to deliver real world advantages, announced today that the company has been awarded a single award Indefinite Delivery Indefinite Quantity (IDIQ) by the U.S. Army for a Digital Night Vision Technology (DNVT) contract worth up to $92.6M over four years.

Key Points: 
  • Lorton, VA, March 30, 2023 (GLOBE NEWSWIRE) -- QinetiQ US, a leading defense company providing mission-critical solutions to create, test, and use the latest technologies to deliver real world advantages, announced today that the company has been awarded a single award Indefinite Delivery Indefinite Quantity (IDIQ) by the U.S. Army for a Digital Night Vision Technology (DNVT) contract worth up to $92.6M over four years.
  • The DNVT effort utilizes and continues more than two decades of Department of Defense (DoD) science and technology (S&T) research, development, and investment into digital visible, low-light level (LLL) and infrared cameras, image processing and display component technologies, and integrated systems.
  • DNVT will substantially enhance the warfighter’s situational awareness (SA) and decision-making abilities by developing digital night vision capabilities coupled with component technology enhancements including fused imagers, display enhancements, and image processing hardware and algorithms.
  • “Digital Night Vision Technology will better enable soldiers to view and understand information in tactical environments allowing them to react and respond to real-time data,” said Shawn Purvis, President and CEO of QinetiQ US “We are proud to support the critical needs of our U.S. Army customers.”

Learn Look Locate (LLL) Has Expanded Its Medical Advisory Board to Include an Expert from Walgreens to Further Advance the Organization's Mission of Providing People Living with Breast Cancer with Critical Health Information and Resources

Retrieved on: 
Thursday, February 16, 2023
Caregiver, Nail, Feel, Breast cancer, Patient, Skin, Health, LLL, Research, Hair, Partnership, Social media, Cancer, Nursing, Walgreens

"Today I'm pleased to announce that Dr. Alex Cosimano, a Walgreens specialty pharmacy manager and pharmacist, will join Learn Look Locate's team of medical advisors."

Key Points: 
  • "Today I'm pleased to announce that Dr. Alex Cosimano, a Walgreens specialty pharmacy manager and pharmacist, will join Learn Look Locate's team of medical advisors."
  • Dr. Barry Rosen, breast surgeon and senior medical advisor for Learn Look Locate welcomes the new partnership.
  • "We are thrilled to have Walgreens be part of the Learn Look Locate team and mission because they provide so many valuable resources," he said.
  • "It is such an honor to be a part of this collaboration between Learn Look Locate and Walgreens," Cosimano said.

Learn Look Locate Partners with Genetic Testing Leader, Myriad Genetics, in Educational Campaign

Retrieved on: 
Thursday, October 13, 2022
Physician, LinkedIn, Genetics, News, Disease, Risk, Risk assessment, LLL, Diagnosis, Survivor, Fast Company, Education, Society, Patient, Research, Twitter, HIV disease progression rates, Instagram, Facebook, Cancer, Learning, Precision medicine, Knowledge, Technology, Myriad Genetics, Partnership, World, Texas Oncology, Health, Myriad, Breast cancer, Awareness, Social media, Genetic testing, Metastasis, Genetic, Gene, Pharmaceutical industry, Medical imaging

TUCSON, Ariz., Oct. 13, 2022 /PRNewswire/ -- Learn Look Locate (LLL) announced a partnership with Myriad Genetics , a leader in genetic testing and precision medicine, to advance awareness about hereditary breast cancer and risk assessment.

Key Points: 
  • TUCSON, Ariz., Oct. 13, 2022 /PRNewswire/ -- Learn Look Locate (LLL) announced a partnership with Myriad Genetics , a leader in genetic testing and precision medicine, to advance awareness about hereditary breast cancer and risk assessment.
  • As part of the partnership, Myriad will share educational information for breast cancer patients and survivors on LLL's doctor monitored and curated platform.
  • "We are partnering with Learn Look Locate to help further educate patients and healthcare providers about hereditary cancer testing," said Thomas Slavin, M.D., chief medical officer, Myriad Genetics.
  • The American Society of Breast Surgeons (ASBrS) recommends testing of all patients diagnosed with breast cancer.

6-Month Data from the Surmodics SWING BTK First-in-Human Trial Presented at AMP Europe

Retrieved on: 
Tuesday, October 11, 2022
Health, Medical Devices, Surgery, General Health, Clinical Trials, Pharmaceutical, Cardiology, Disease, Sale, SEC, LLL, MS, Population, CLI, Growth, Investor, FIH, PHD, Annual report, NASDAQ, DCB, Cell, Amputation, Restenosis, Technology, ONZM, Company, IVD, MD, RVD, Safety, Diabetes, AMP, FRANZCR, Master of Medicine, Forward-looking statement, Aortoiliac occlusive disease, Medical device, Pharmaceutical industry, FRACS, MBBS, Bachelor of Medicine, Bachelor of Surgery

The studys primary safety endpoint data showed no perioperative deaths or major amputations at 30 days and just one major re-intervention was reported among the 35 trial subjects.

Key Points: 
  • The studys primary safety endpoint data showed no perioperative deaths or major amputations at 30 days and just one major re-intervention was reported among the 35 trial subjects.
  • The Sundance Sirolimus Drug-Coated Balloon is not available for sale anywhere in the world, and currently is for investigational use only.
  • Surmodics is pursuing highly differentiated medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements.
  • The content of Surmodics website is not part of this press release or part of any filings that the company makes with the SEC.

JX Luxventure Limited Announces Change of Its Trading Symbol

Retrieved on: 
Monday, October 10, 2022
U.S. Securities and Exchange Commission, LLL, E-commerce, Person, NASDAQ, Security (finance), Private Securities Litigation Reform Act, Company, SAAS, Tourism, Nasdaq, Solution, Online shopping

Headquartered inHaikou, China, JX Luxventure Limited is a company delivering comprehensive products solutions to global elite families serviced by our business customers with business segments covering menswear, cross-border merchandiseand tourism.

Key Points: 
  • Headquartered inHaikou, China, JX Luxventure Limited is a company delivering comprehensive products solutions to global elite families serviced by our business customers with business segments covering menswear, cross-border merchandiseand tourism.
  • This press release may contain certain "forward-looking statements" relating to the business of JX Luxventure Limited, and its subsidiary companies.
  • Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release.
  • Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

JX Luxventure Limited Signs Pet Food Agreement with a Leading Distributor in China for $20,000,000 Annual Sales Amount

Retrieved on: 
Monday, October 3, 2022
Solution, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, E-commerce, Growth, Agreement, Sale, Heilongjiang Longmay Mining Holding Group Co., Ltd., Security (finance), Person, SAAS, LLL, Contract, Marketing, Good, Company, Tourism

The Agreement provides that the target annual sales amount of JXFC's pet food products is $20,000,000 and if HS Zhongli achieves this targeted annual sales amount, the Agreement will be automatically renewed for an additional year.

Key Points: 
  • The Agreement provides that the target annual sales amount of JXFC's pet food products is $20,000,000 and if HS Zhongli achieves this targeted annual sales amount, the Agreement will be automatically renewed for an additional year.
  • This is the second year of the three-year turn-around strategy, and we are very pleased with the execution thus far.
  • This press release may contain certain "forward-looking statements" relating to the business of JX Luxventure Limited, and its subsidiary companies.
  • Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.